Infectious Diseases

INFECTIOUS DISEASE RESEARCH IS MAKING GREAT ADVANCES

Worldwide, infectious diseases are one of the leading causes of death in adults and are the leading cause of death of children and adolescents. Each year, at least sixteen percent of all deaths are from infectious diseases. Vaccines play a critical role in reducing childhood mortality with an estimated 1.3 million lives saved each year.

The threat of infectious disease is persistent, and it is rapidly growing, sometimes faster than biopharma’s ability to respond. As new markets and bio-threats are identified for conducting clinical research, our experienced team is already prepared and starts clinical trails quickly and efficiently.

The WCCT Global research unit works to streamline clinical development of new vaccines, delivery systems, treatments and antimicrobial agents to post-approval in a timely, cost-effective manner. Partner with a leader who has a track record in infectious diseases:

WCCT Global Influenza and Infectious Disease Experience

  • Bacterial Infection
  • Bacterial Nosocomial Infections
  • Chronic Hepatitis C
  • Chronic Hepatitis B
  • Complicated Skin infections
  • Fungal Infections
  • Herpes Zoster
  • Influenza

Vaccines

The WCCT Global vaccine trial experience spans multiple therapeutic indications and all age groups including:

  • Seasonal Influenza
  • Pandemic Influenza
  • Hepatitis B
  • Herpes Zoster

The Challenges of Vaccine Trials

Vaccines using new, more advanced technologies are rapidly being developed. These technologies include cell-based manufacture (insect, bacterial, and mammalian), DNA vaccines, and therapeutic vaccines. New delivery methods, such a patch-based and electroporation are revolutionizing vaccine technologies. Even the trivalent Influenza vaccine is being re-evaluated for efficacy, and there is now research that suggests a universal flu vaccine is possible within the next few years.

These new technologies and vaccine products are rapidly advancing and are requiring that vaccine developers find strategies to meet FDA licensure requirement in a timely manner. This is important because these new products represent the potential to fight diseases that cause the deaths of thousands in the United States every year. WCCT Global wants to partner with vaccine developers to make sure that clinical trials are designed to withstand scientific and regulatory scrutiny.

WCCT Global has deep expertise in the areas of new vaccine technologies and both therapeutic and preventative vaccine clinical development. Their experts also have a sophisticated understanding of FDA regulations and requirements for vaccine approval. WCCT Global is in the unique position to streamline clinical development of new vaccines and delivery systems, saving money and time.

Data Management solutions that work for any site, Clinical Solutions that yield the patients, Statistical Analysis that makes sense, Monitoring and Pharmacovigilance that follow new industry standards and Project Management solutions that keep everyone on time and on budget.

Shingles, also known as zoster, herpes zoster, or zona, is a viral disease characterized by a painful skin rash with blistersinvolving a limited area.[1][2] Typically the rash occurs on either the left or right of the body or face in a single stripe. Two to four days before the rash occurs there may be pain or tingling in the area. Otherwise there are typically few symptoms.[3] The rash usually heals within two to four weeks;[1] however, some people develop ongoing nerve pain which may last for months or years, a condition called postherpetic neuralgia. In those with poor immune function the rash may occur widely.[3] If the rash involves the eye, vision loss may occur.
 A vaccine trial is a clinical trial that aims at establishing the safety and efficacy of a vaccine prior to it being licensed. Understanding vaccine safety and the immunological response to the drug, such as toxicity, are necessary components of the preclinical stage. Other drug trials focus on the pharmacodynamics and pharmacokinetics; however,
Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the relative costs and outcomes (effects) of two or more courses of action. Cost-effectiveness analysis is distinct from cost–benefit analysis, which assigns a monetary value to the measure of effect.[1] Cost-effectiveness analysis is often used in the field of health services, where it may be inappropriate to monetize health effect. Typically the CEA is expressed in terms of a ratio where the denominator is a gain in health from a measure (years of life, premature births averted, sight-years gained) and the numerator is the cost associated with the health gain.[2] The most commonly used outcome measure is quality-adjusted life years (QALY).[1] Cost-utility analysis is similar to cost-effectiveness analysis.